Hmmm,
@Steini and
@dalts66 either of you honorable enough to admit I was right?
I explained why the L1 facility was not going to work
And now CHM has to rely on Hopper's "sophisticated" mates only this time they're coming off:
(a) a string of under-water capital raises across his biotech businesses; and
(b) CHM's management all but confirming no chance of positive trial progress reporting before year's-end at best (so limited chance to dump on market for a short term profit).
I'll be seriously impressed if the cap-raise gets away above 4c, and more impressed if the SP doesn't drop below 2c prior to year-end. Almost getting to an existential threat with this one ...
(and FYI dalts66, the 4c is not an "audited report", its just filled out internally).
(20min delay)